Media stories about Minerva Neurosciences (NASDAQ:NERV) have trended somewhat negative on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Minerva Neurosciences earned a news sentiment score of 0.00 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.9772160338278 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Minerva Neurosciences traded down $0.05, reaching $8.40, during trading on Wednesday, Marketbeat Ratings reports. The company’s stock had a trading volume of 3,763 shares, compared to its average volume of 149,170. The stock has a market capitalization of $333.24 million, a price-to-earnings ratio of -7.78 and a beta of 1.55. Minerva Neurosciences has a 1-year low of $4.80 and a 1-year high of $9.25.
Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.04). equities research analysts forecast that Minerva Neurosciences will post -1.46 EPS for the current year.
NERV has been the topic of a number of analyst reports. BidaskClub upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating in a report on Saturday, June 16th. ValuEngine upgraded Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a report on Thursday, May 3rd. Finally, Zacks Investment Research downgraded Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Tuesday, May 15th.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.